Skip to content

    Recently Viewed

      Listening...

      Johnson & Johnson’s Sandi Peterson (left) and Jennifer Taubert from Fortune's 2017 Most Powerful Women List

      Johnson & Johnson leaders make Fortune‘s 2017 Most Powerful Women list

      Group Worldwide Chair Sandi Peterson and Company Group Chairman, Pharmaceuticals, The Americas Jennifer Taubert are honorees once again this year.

      Share Article
      share to

      Two of Johnson & Johnson’s top leaders have made Fortune magazine’s list of Most Powerful Women: Group Worldwide Chair Sandi Peterson and Company Group Chairman, Pharmaceuticals, The Americas Jennifer Taubert—both of whom made the 2016 list.

      Each year since 1998, Fortune has highlighted 50 women who are leading in their industries—and transforming their businesses along the way.

      Peterson, who has appeared on the prestigious list five times and secured the #22 ranking this year, recently expanded her role at Johnson & Johnson to include oversight of the company’s hospital medical devices business, in addition to her existing responsibilities overseeing consumer and consumer medical devices, global design, global services, health technology, health & wellness, information technology and supply chain.

      The secret to her success? In a word, “optimism.”

      Since Johnson & Johnson was founded, women have been at the center of the story. More than half of the initial 14 employees were female, and today we have a vibrant, diverse group of leaders across our enterprise.
      Jennifer Taubert

      “It’s not in my DNA to say we can’t, we don’t, we’ve never,” Peterson says. “To be bold and make a difference, we need to experiment, test and learn, and do things differently. I think the most important lesson I’ve learned over the course of my career is the importance of intellectual curiosity, agility of learning, and relying on other people and figuring out how to get the best out of them.”

      Since debuting on last year’s list, Taubert—who oversees innovation-based growth from Canada to South America for the company’s pharmaceutical division—spearheaded the release of the company’s 2016 U.S. Transparency Report, which sought to address questions about drug pricing and other company practices. She has also been named by the National Association for Female Executives (NAFE) as a 2017 NAFE Woman of Excellence in honor of her career success and her efforts to boost the progress of women and girls.

      To Taubert, who nabbed the #43 ranking this year, it makes sense that more than one company leader is being feted by Fortune.

      “Since Johnson & Johnson was founded, women have been at the center of the story,” she points out. “More than half of the initial 14 employees were female, and today we have a vibrant, diverse group of leaders across our enterprise. Our representation on the list is an extraordinary hallmark in our continued efforts to ensure that Johnson & Johnson embodies diversity and inclusion in all that we do.”

      Powerful Women—and Powerful Mentors

      Learn how Peterson and Taubert are nurturing the next generation of global women leaders in this video.

      More from Johnson & Johnson

      Innovation
      Two cardiac electrophysiologists performing a cardiac ablation procedure to treat AFib

      What is cardiac ablation?

      For American Heart Month, learn how Johnson & Johnson is innovating to help treat the millions of people who are living with atrial fibrillation and other conditions that cause an irregular heartbeat.
      Latest news
       Biomedical scientist Robert Langer headshot

      Biomedical scientist Robert Langer receives the 2023 Dr. Paul Janssen Award for Biomedical Research

      Each year, Johnson & Johnson honors a scientist currently working in academia, industry or a scientific institute who has made a significant contribution toward the improvement of public health.
      Health & wellness
       Blue latex gloved hand pointing at a brain MRI scan to pinpoint brain circuits associated with depression symptoms

      Is this the end of one-size-fits-all treatments for depression?

      Johnson & Johnson is working to bring personalized psychiatry to the 7 in 10 people with depression whose treatments aren’t getting the job done.
      You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.